Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.
At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.
Solid Tumor Testing Market by Type (Genetic Testing(NGS, RT-PCR, FISH, Fragment Analysis), Conventional Testing), by Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Brain Cancer, Thyroid Cancer, Liver Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Others), by End User (Hospitals, Diagnostics Laboratories, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Cancer Research Institutes, Academic Research Institutions), by Sample Type (Tissue Biopsy, Liquid Biopsy, Other Body Fluids), by Technology (NGS, PCR, IHC, FISH, Others), by North America (USA, Canada, Mexico), by Europe (Germany, UK, France, Italy, Spain), by Asia Pacific (China, Japan, India, South Korea, Australia), by South America (Brazil, Argentina), by Middle East & Africa (Saudi Arabia, South Africa) Forecast 2026-2034
Updated On : Nov 4, 2026|Base Year : 2025|Pages : 225
Executive Overview: A Market Anchored in Precision Oncology
Our proprietary primary research estimates the global solid tumor testing market at USD 20.5 billion in 2023, expanding at 7.6% CAGR to reach USD 39.4 billion by 2032. This trajectory reflects the structural embedding of molecular diagnostics into routine oncology pathways, with genetic testing commanding USD 13.6 billion in 2023 — roughly two-thirds of total market value. A total of 1.78 million new invasive cancer cases were recorded in the U.S. in 2021 alone, underscoring the volume-based foundation of this market.
Solid Tumor Testing Market Size (In Billion)
40.0B
30.0B
20.0B
10.0B
0
23.73 B
2025
25.54 B
2026
27.48 B
2027
29.57 B
2028
31.82 B
2029
34.23 B
2030
36.83 B
2031
Solid Tumor Testing Market Size (In Billion)
Year
Market Size
2025
23.73 B
2026
25.54 B
2027
27.48 B
2028
29.57 B
2029
31.82 B
2030
34.23 B
2031
36.83 B
The market is undergoing a decisive shift from single-analyte assays toward comprehensive genomic profiling (CGP). Next-generation sequencing (NGS) now underpins 54.55% of technology-based value in the solid tumor testing space, while tissue biopsy retains 61.23% of sample-type share as of our latest base-year estimates. Liquid biopsy is advancing at a 15.55% CAGR through 2031, positioning blood-based testing as the most dynamic sub-segment. Asia-Pacific represents the fastest-growing region at 12.21% CAGR, while North America holds 42.25% of global revenue.
Metric
Value
Base Year Market Size (2023)
USD 20.5 Billion
Forecast Market Size (2032)
USD 39.4 Billion
CAGR (2024–2032)
7.6%
Genetic Testing Segment Share (2023)
USD 13.6 Billion
Largest Application (Breast Cancer)
25.9% share
Largest Regional Market (North America)
42.25% share (2025)
Fastest-Growing Region
Asia-Pacific (12.21% CAGR)
Market Drivers: Incidence, Precision Guidelines, and Cost Deflation
Demand fundamentals rest on three converging forces identified through our executive interview program with 340+ oncology stakeholders.
Aging-Driven Incidence: Cancer incidence rises steeply with age. Japan's over-65 cohort reached 29% in 2024, and the U.S. is projected to hit 21% by 2030, sustaining durable test volume even at flat reimbursement levels.
Guideline-Mandated Molecular Profiling: The 2024 ASCO lung-cancer guideline update requires reflex NGS or sequential assays for at least eight biomarkers prior to first-line therapy selection. This converts molecular testing from an optional add-on into a standard-of-care gate for treatment access.
Falling NGS Cost Curve: Sequencing reagent prices have declined by an order of magnitude over the past decade. Per-sample expenses drop from approximately USD 377 to USD 128 when annual laboratory throughput rises from 600 to 5,000 samples, significantly widening reference-lab margins.
Tumor-Agnostic Approvals: FDA clearances in 2024 for NRG1-fusion and NTRK-positive indications require broad panels capable of detecting rare fusions across histologies, amplifying demand for pan-cancer testing.
Companion Diagnostic Linkage: New targeted therapies create recurring, therapy-linked demand as each approval expands the actionable mutation set that laboratories must cover.
Restraints and Challenges: Reimbursement, Tissue Sufficiency, and Interpretation Complexity
Our analysis quantifies the friction points that temper growth to a still-robust 7.6% CAGR rather than a double-digit expansion.
Patchy Reimbursement: Comprehensive panels priced between USD 3,000 and USD 5,000 strain oncology budgets outside academic centers. Europe remains fragmented — Germany broadened NGS coverage in 2024, while France mandates case-by-case molecular tumor board approval.
Tissue Insufficiency: Small biopsies frequently yield insufficient material for broad profiling. This delay is a primary structural driver of liquid biopsy adoption as a complementary pathway.
Molecular Pathologist Shortage: Fewer than 200 new U.S. specialists graduate annually, well below projected need. India counts fewer than 50 certified molecular pathologists for a population of 1.4 billion, constraining turnaround times globally.
Tumor Heterogeneity: A single biopsy captures only a portion of a tumor at one point in time, and molecular characteristics evolve under treatment pressure. Larger panels generate data but not always actionable findings, placing a premium on bioinformatics interpretation.
High Capital Requirements: Establishing an in-house CGP laboratory entails substantial instrument, validation, and informatics investment, limiting adoption to large health systems and reference laboratories.
Segmentation Analysis: Genetic Testing and Breast Cancer Lead, Lung Accelerates
Our segmentation framework applies a bottom-up build across type, application, end-user, and technology layers.
Segment Dimension
Leading Category
Share / Metric
Fastest-Growing Category
Type
Genetic Testing
USD 13.6 Billion (2023)
Liquid biopsy-adjacent NGS workflows
Application
Breast Cancer
25.9% share (2023)
Lung Cancer (10.72% CAGR)
End User
Hospitals
USD 13.8 Billion by 2032
Diagnostic & reference laboratories (10.11% CAGR)
Technology
NGS
54.55% share (2025)
FISH (10.25% CAGR)
Sample Type
Tissue Biopsy
61.23% share (2025)
Liquid Biopsy (15.55% CAGR)
Breast cancer's dominance is anchored in routine HER2 and hormone receptor testing embedded in pathology review, with BRCA1/BRCA2 germline assessment standard in many markets. Lung cancer's 10.72% CAGR reflects the density of actionable alterations and the breadth of companion diagnostics in that indication. Hospitals maintain their lead because they serve as the first point of contact for cancer diagnosis and host multidisciplinary tumor boards, though reference laboratories are growing faster as health networks outsource complex molecular work.
Regional Outlook: North America Dominates, Asia-Pacific Accelerates
North America generated USD 7.7 billion in 2023, growing at 7.3% CAGR, with the U.S. alone accounting for USD 7.1 billion. The region's advantage stems from established reimbursement codes (NCD 90.2), widespread CGP adoption, and concentration of leading diagnostic innovators.
Solid Tumor Testing Market Regional Market Share
Loading chart...
Solid Tumor Testing Market Regional Market Share
Region
Market Share (%)
North America
0.42%
Europe
0.24%
Asia-Pacific
0.26%
South America
0.04%
Middle East & Africa
0.04%
Asia-Pacific is the fastest-growing geography at 12.21% CAGR, supported by medical tourism expansion, healthcare infrastructure modernization in China and India, and regulatory reform in Japan. Country-level growth momentum varies: South Korea at 5.8% CAGR, the U.S. at 9.4%, Australia at 5.1%, Canada at 6.5%, Germany at 7.9%, the UK at 7.2%, and Japan at 8.6% through 2036. Europe's trajectory is shaped by IVDR certification bottlenecks, which we estimate trim approximately 0.4 percentage points from regional CAGR over the medium term.
Competitive Landscape and Strategic Developments
The market is moderately concentrated, with vertically integrated diagnostics majors, sequencing platform providers, and specialized reference laboratories competing on menu breadth, turnaround time, and interpretation quality.
F. Hoffmann-La Roche Ltd secured FDA approval in August 2021 for the VENTANA MMR RxDx Panel, the first companion diagnostic to identify dMMR-deficient solid tumors for targeted therapy.
Guardant Health received FDA approval in May 2026 for Guardant360 Liquid CDx, assessing a genomic footprint 100 times wider than the prior version and integrating genomic with epigenomic profiling.
Illumina advanced the cost frontier with the NovaSeq X Plus targeting a USD 600 genome by 2025, while BGI Genomics advertises sub-USD 100 costs at scale.
Thermo Fisher Scientific's TruSight Oncology 500 kit enables hospitals to run FDA-cleared CGP in-house, supporting the observed shift where 38% of U.S. cancer centers now perform NGS internally.
Competitive differentiation increasingly hinges on connecting assay performance to reimbursement support, clear reporting, and bioinformatics interpretation — providers that deliver this bundle are winning hospital accounts.
Strategic Opportunities: Repeated Monitoring and Workflow Integration
The most significant white space lies in converting solid tumor testing from a one-time diagnostic event into a longitudinal monitoring service. Blood-based ctDNA testing enables repeat sampling that can identify emerging resistance mutations before imaging progression, creating recurring revenue across a patient's treatment journey.
Liquid Biopsy Add-On Menus: Estimated to contribute +0.7% incremental CAGR geographically concentrated in the U.S., Germany, and the UK over the long term.
Hospital In-House CGP Kits: The shift to internal NGS operations adds approximately +0.9% CAGR in North America and Western Europe over the medium term.
Breast Cancer Workflow Packages: Bundling HER2 and hormone receptor testing reduces ordering friction and adds an estimated +1.1% CAGR in South Korea and the U.S.
AI-Assisted Multi-Omic Interpretation: Adds approximately +0.8% CAGR globally, with early adoption concentrated in U.S. academic centers.
Providers that pair assay performance with reimbursement navigation and readable clinical reporting are best positioned to capture hospital accounts as oncology menus expand.
Solid Tumor Testing Market Regional Market Share
Higher Coverage
Lower Coverage
No Coverage
Solid Tumor Testing Market REPORT HIGHLIGHTS
Aspects
Details
Study Period
2020-2034
Base Year
2025
Estimated Year
2026
Forecast Period
2026-2034
Historical Period
2020-2025
Growth Rate
CAGR of 7.6% from 2020-2034
Segmentation
By Type
Genetic Testing(NGS, RT-PCR, FISH, Fragment Analysis)
Conventional Testing
By Application
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Brain Cancer
Thyroid Cancer
Liver Cancer
Ovarian Cancer
Endometrial Cancer
Cervical Cancer
Others
By End User
Hospitals
Diagnostics Laboratories
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Cancer Research Institutes
Academic Research Institutions
By Sample Type
Tissue Biopsy
Liquid Biopsy
Other Body Fluids
By Technology
NGS
PCR
IHC
FISH
Others
By Geography
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Asia Pacific
China
Japan
India
South Korea
Australia
South America
Brazil
Argentina
Middle East & Africa
Saudi Arabia
South Africa
Table of Contents
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Objective
1.4. Definitions and Assumptions
2. Executive Summary
2.1. Market Snapshot
3. Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Trends
3.4. Market Opportunity
4. Market Factor Analysis
4.1. Porters Five Forces
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL analysis
4.3. BCG Analysis
4.3.1. Stars (High Growth, High Market Share)
4.3.2. Cash Cows (Low Growth, High Market Share)
4.3.3. Question Mark (High Growth, Low Market Share)
4.3.4. Dogs (Low Growth, Low Market Share)
4.4. Ansoff Matrix Analysis
4.5. Supply Chain Analysis
4.6. Regulatory Landscape
4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
4.8. MIQ Analyst Note
5. Market Analysis, Insights and Forecast, 2020-2034
5.1. Market Analysis, Insights and Forecast - by Type
5.1.1. Genetic Testing(NGS, RT-PCR, FISH, Fragment Analysis)
5.1.2. Conventional Testing
5.2. Market Analysis, Insights and Forecast - by Application
5.2.1. Breast Cancer
5.2.2. Lung Cancer
5.2.3. Colorectal Cancer
5.2.4. Prostate Cancer
5.2.5. Melanoma
5.2.6. Brain Cancer
5.2.7. Thyroid Cancer
5.2.8. Liver Cancer
5.2.9. Ovarian Cancer
5.2.10. Endometrial Cancer
5.2.11. Cervical Cancer
5.2.12. Others
5.3. Market Analysis, Insights and Forecast - by End User
5.3.1. Hospitals
5.3.2. Diagnostics Laboratories
5.3.3. Pharmaceutical and Biotechnology Companies
5.3.4. Contract Research Organizations
5.3.5. Cancer Research Institutes
5.3.6. Academic Research Institutions
5.4. Market Analysis, Insights and Forecast - by Sample Type
5.4.1. Tissue Biopsy
5.4.2. Liquid Biopsy
5.4.3. Other Body Fluids
5.5. Market Analysis, Insights and Forecast - by Technology
5.5.1. NGS
5.5.2. PCR
5.5.3. IHC
5.5.4. FISH
5.5.5. Others
5.6. Market Analysis, Insights and Forecast - by Region
5.6.1. North America
5.6.2. Europe
5.6.3. Asia Pacific
5.6.4. South America
5.6.5. Middle East & Africa
6. North America Market Analysis, Insights and Forecast, 2020-2034
6.1. Market Analysis, Insights and Forecast - by Type
6.1.1. Genetic Testing(NGS, RT-PCR, FISH, Fragment Analysis)
6.1.2. Conventional Testing
6.2. Market Analysis, Insights and Forecast - by Application
6.2.1. Breast Cancer
6.2.2. Lung Cancer
6.2.3. Colorectal Cancer
6.2.4. Prostate Cancer
6.2.5. Melanoma
6.2.6. Brain Cancer
6.2.7. Thyroid Cancer
6.2.8. Liver Cancer
6.2.9. Ovarian Cancer
6.2.10. Endometrial Cancer
6.2.11. Cervical Cancer
6.2.12. Others
6.3. Market Analysis, Insights and Forecast - by End User
6.3.1. Hospitals
6.3.2. Diagnostics Laboratories
6.3.3. Pharmaceutical and Biotechnology Companies
6.3.4. Contract Research Organizations
6.3.5. Cancer Research Institutes
6.3.6. Academic Research Institutions
6.4. Market Analysis, Insights and Forecast - by Sample Type
6.4.1. Tissue Biopsy
6.4.2. Liquid Biopsy
6.4.3. Other Body Fluids
6.5. Market Analysis, Insights and Forecast - by Technology
6.5.1. NGS
6.5.2. PCR
6.5.3. IHC
6.5.4. FISH
6.5.5. Others
7. Europe Market Analysis, Insights and Forecast, 2020-2034
7.1. Market Analysis, Insights and Forecast - by Type
7.1.1. Genetic Testing(NGS, RT-PCR, FISH, Fragment Analysis)
7.1.2. Conventional Testing
7.2. Market Analysis, Insights and Forecast - by Application
7.2.1. Breast Cancer
7.2.2. Lung Cancer
7.2.3. Colorectal Cancer
7.2.4. Prostate Cancer
7.2.5. Melanoma
7.2.6. Brain Cancer
7.2.7. Thyroid Cancer
7.2.8. Liver Cancer
7.2.9. Ovarian Cancer
7.2.10. Endometrial Cancer
7.2.11. Cervical Cancer
7.2.12. Others
7.3. Market Analysis, Insights and Forecast - by End User
7.3.1. Hospitals
7.3.2. Diagnostics Laboratories
7.3.3. Pharmaceutical and Biotechnology Companies
7.3.4. Contract Research Organizations
7.3.5. Cancer Research Institutes
7.3.6. Academic Research Institutions
7.4. Market Analysis, Insights and Forecast - by Sample Type
7.4.1. Tissue Biopsy
7.4.2. Liquid Biopsy
7.4.3. Other Body Fluids
7.5. Market Analysis, Insights and Forecast - by Technology
7.5.1. NGS
7.5.2. PCR
7.5.3. IHC
7.5.4. FISH
7.5.5. Others
8. Asia Pacific Market Analysis, Insights and Forecast, 2020-2034
8.1. Market Analysis, Insights and Forecast - by Type
8.1.1. Genetic Testing(NGS, RT-PCR, FISH, Fragment Analysis)
8.1.2. Conventional Testing
8.2. Market Analysis, Insights and Forecast - by Application
8.2.1. Breast Cancer
8.2.2. Lung Cancer
8.2.3. Colorectal Cancer
8.2.4. Prostate Cancer
8.2.5. Melanoma
8.2.6. Brain Cancer
8.2.7. Thyroid Cancer
8.2.8. Liver Cancer
8.2.9. Ovarian Cancer
8.2.10. Endometrial Cancer
8.2.11. Cervical Cancer
8.2.12. Others
8.3. Market Analysis, Insights and Forecast - by End User
8.3.1. Hospitals
8.3.2. Diagnostics Laboratories
8.3.3. Pharmaceutical and Biotechnology Companies
8.3.4. Contract Research Organizations
8.3.5. Cancer Research Institutes
8.3.6. Academic Research Institutions
8.4. Market Analysis, Insights and Forecast - by Sample Type
8.4.1. Tissue Biopsy
8.4.2. Liquid Biopsy
8.4.3. Other Body Fluids
8.5. Market Analysis, Insights and Forecast - by Technology
8.5.1. NGS
8.5.2. PCR
8.5.3. IHC
8.5.4. FISH
8.5.5. Others
9. South America Market Analysis, Insights and Forecast, 2020-2034
9.1. Market Analysis, Insights and Forecast - by Type
9.1.1. Genetic Testing(NGS, RT-PCR, FISH, Fragment Analysis)
9.1.2. Conventional Testing
9.2. Market Analysis, Insights and Forecast - by Application
9.2.1. Breast Cancer
9.2.2. Lung Cancer
9.2.3. Colorectal Cancer
9.2.4. Prostate Cancer
9.2.5. Melanoma
9.2.6. Brain Cancer
9.2.7. Thyroid Cancer
9.2.8. Liver Cancer
9.2.9. Ovarian Cancer
9.2.10. Endometrial Cancer
9.2.11. Cervical Cancer
9.2.12. Others
9.3. Market Analysis, Insights and Forecast - by End User
9.3.1. Hospitals
9.3.2. Diagnostics Laboratories
9.3.3. Pharmaceutical and Biotechnology Companies
9.3.4. Contract Research Organizations
9.3.5. Cancer Research Institutes
9.3.6. Academic Research Institutions
9.4. Market Analysis, Insights and Forecast - by Sample Type
9.4.1. Tissue Biopsy
9.4.2. Liquid Biopsy
9.4.3. Other Body Fluids
9.5. Market Analysis, Insights and Forecast - by Technology
9.5.1. NGS
9.5.2. PCR
9.5.3. IHC
9.5.4. FISH
9.5.5. Others
10. Middle East & Africa Market Analysis, Insights and Forecast, 2020-2034
10.1. Market Analysis, Insights and Forecast - by Type
10.1.1. Genetic Testing(NGS, RT-PCR, FISH, Fragment Analysis)
10.1.2. Conventional Testing
10.2. Market Analysis, Insights and Forecast - by Application
10.2.1. Breast Cancer
10.2.2. Lung Cancer
10.2.3. Colorectal Cancer
10.2.4. Prostate Cancer
10.2.5. Melanoma
10.2.6. Brain Cancer
10.2.7. Thyroid Cancer
10.2.8. Liver Cancer
10.2.9. Ovarian Cancer
10.2.10. Endometrial Cancer
10.2.11. Cervical Cancer
10.2.12. Others
10.3. Market Analysis, Insights and Forecast - by End User
10.3.1. Hospitals
10.3.2. Diagnostics Laboratories
10.3.3. Pharmaceutical and Biotechnology Companies
10.3.4. Contract Research Organizations
10.3.5. Cancer Research Institutes
10.3.6. Academic Research Institutions
10.4. Market Analysis, Insights and Forecast - by Sample Type
10.4.1. Tissue Biopsy
10.4.2. Liquid Biopsy
10.4.3. Other Body Fluids
10.5. Market Analysis, Insights and Forecast - by Technology
10.5.1. NGS
10.5.2. PCR
10.5.3. IHC
10.5.4. FISH
10.5.5. Others
11. Competitive Analysis
11.1. Company Profiles
11.1.1. Abbott Laboratories
11.1.1.1. Company Overview
11.1.1.2. Products
11.1.1.3. Company Financials
11.1.1.4. SWOT Analysis
11.1.2. Agilent Technologies Inc.
11.1.2.1. Company Overview
11.1.2.2. Products
11.1.2.3. Company Financials
11.1.2.4. SWOT Analysis
11.1.3. Biocare Medical LLC
11.1.3.1. Company Overview
11.1.3.2. Products
11.1.3.3. Company Financials
11.1.3.4. SWOT Analysis
11.1.4. Caris Life Sciences
11.1.4.1. Company Overview
11.1.4.2. Products
11.1.4.3. Company Financials
11.1.4.4. SWOT Analysis
11.1.5. Exact Sciences
11.1.5.1. Company Overview
11.1.5.2. Products
11.1.5.3. Company Financials
11.1.5.4. SWOT Analysis
11.1.6. F. Hoffmann-La Roche Ltd
11.1.6.1. Company Overview
11.1.6.2. Products
11.1.6.3. Company Financials
11.1.6.4. SWOT Analysis
11.1.7. Foundation Medicine Inc.
11.1.7.1. Company Overview
11.1.7.2. Products
11.1.7.3. Company Financials
11.1.7.4. SWOT Analysis
11.1.8. Guardant Health Inc.
11.1.8.1. Company Overview
11.1.8.2. Products
11.1.8.3. Company Financials
11.1.8.4. SWOT Analysis
11.1.9. Hologic Inc.
11.1.9.1. Company Overview
12. Research Methodology
List of Figures
Figure 1: Solid Tumor Testing Market Revenue Breakdown (Billion, %) by Region 2026 & 2034
Figure 2: North America Solid Tumor Testing Market Revenue (Billion), by Type 2026 & 2034
Figure 3: North America Solid Tumor Testing Market Revenue Share (%), by Type 2026 & 2034
Figure 4: North America Solid Tumor Testing Market Revenue (Billion), by Application 2026 & 2034
Figure 5: North America Solid Tumor Testing Market Revenue Share (%), by Application 2026 & 2034
Figure 6: North America Solid Tumor Testing Market Revenue (Billion), by End User 2026 & 2034
Figure 7: North America Solid Tumor Testing Market Revenue Share (%), by End User 2026 & 2034
Figure 8: North America Solid Tumor Testing Market Revenue (Billion), by Sample Type 2026 & 2034
Figure 9: North America Solid Tumor Testing Market Revenue Share (%), by Sample Type 2026 & 2034
Figure 10: North America Solid Tumor Testing Market Revenue (Billion), by Technology 2026 & 2034
Figure 11: North America Solid Tumor Testing Market Revenue Share (%), by Technology 2026 & 2034
Figure 12: North America Solid Tumor Testing Market Revenue (Billion), by Country 2026 & 2034
Figure 13: North America Solid Tumor Testing Market Revenue Share (%), by Country 2026 & 2034
Figure 14: Europe Solid Tumor Testing Market Revenue (Billion), by Type 2026 & 2034
Figure 15: Europe Solid Tumor Testing Market Revenue Share (%), by Type 2026 & 2034
Figure 16: Europe Solid Tumor Testing Market Revenue (Billion), by Application 2026 & 2034
List of Tables
Table 1: Solid Tumor Testing Market Revenue Billion Forecast, by Type 2020 & 2034
Table 16: Europe Solid Tumor Testing Market Revenue Billion Forecast, by Type 2020 & 2034
Frequently Asked Questions
1. What is the current size of the solid tumor testing market?
The global solid tumor testing market was valued at approximately USD 20.5 billion in 2023 and is projected to reach USD 39.4 billion by 2032, expanding at a 7.6% CAGR. Genetic testing accounted for USD 13.6 billion of the 2023 total, representing roughly two-thirds of market value.
2. Which cancer type dominates solid tumor testing demand?
Breast cancer held a 25.9% share of the market in 2023, driven by routine HER2 and hormone receptor testing and widespread BRCA1/BRCA2 screening programs. Lung cancer is the fastest-growing application, forecast to expand at a 10.72% CAGR through the early 2030s.
3. Why is liquid biopsy growing so quickly in solid tumor testing?
Liquid biopsy is advancing at a 15.55% CAGR because it addresses tissue insufficiency and enables repeated monitoring without invasive procedures. However, tissue biopsy still commands 61.23% of sample-type share due to higher tumor-fraction yield and established reimbursement codes.
4. Which region leads the solid tumor testing market?
North America led with approximately 42.25% of global revenue, supported by established reimbursement frameworks and high CGP adoption in the U.S., which alone generated USD 7.1 billion in 2023. Asia-Pacific is the fastest-growing region at a 12.21% CAGR through 2031.
5. What is the main restraint on solid tumor testing market growth?
High comprehensive panel costs of USD 3,000 to USD 5,000 and patchy reimbursement across commercial payers constrain adoption, particularly in community oncology settings. A shortage of trained molecular pathologists — fewer than 200 new U.S. graduates annually — further slows turnaround times and limits laboratory capacity.
6. Who are the leading companies in solid tumor testing?
Key participants include F. Hoffmann-La Roche, Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, Guardant Health, Myriad Genetics, NeoGenomics, Foundation Medicine, Caris Life Sciences, and Quest Diagnostics. Competition centers on menu breadth, turnaround time, and AI-assisted interpretation capabilities.
Research Methodology & Data Sources
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
Primary Research
Our analysis is built on a 70–80% primary research / 20–30% secondary research split, with primary intelligence gathered through structured interviews and expert consultations across the solid tumor testing value chain.
We conducted 340+ in-depth interviews globally, targeting four specific company types: IVD and companion diagnostic manufacturers, hospital and cancer center molecular pathology laboratories, reference and contract diagnostic service providers, and next-generation sequencing platform and bioinformatics software vendors.
Interviewees included Chief of Molecular Pathology, Director of Companion Diagnostics, Laboratory Operations Manager, and VP of Oncology Diagnostics — roles with direct accountability for test menu decisions, reimbursement strategy, and platform procurement.
We benchmark regulatory and standards frameworks against globally recognized bodies including the U.S. Food and Drug Administration (FDA), the College of American Pathologists (CAP), the European Medicines Agency (EMA), and the National Comprehensive Cancer Network (NCCN) clinical guidelines.
Key Stakeholders Interviewed
Key Stakeholders Interviewed
Stakeholder Role
Interview Share (%)
Chief of Molecular Pathology
34%
Director of Companion Diagnostics
28%
Laboratory Operations Manager
22%
VP of Oncology Diagnostics
16%
Industry Ecosystem Breakdown
Industry Ecosystem Breakdown
Company Type
Representation (%)
IVD & Companion Diagnostic Manufacturers
38%
Hospital & Cancer Center Molecular Labs
27%
Reference & Contract Diagnostic Providers
22%
NGS Platform & Bioinformatics Vendors
13%
Secondary Research & Industry Benchmarking
Secondary inputs are drawn from official multilateral and governmental institutions — including the World Health Organization (WHO), the U.S. National Cancer Institute (NCI), the Centers for Disease Control and Prevention (CDC), Eurostat, and OECD Health Statistics — as well as peer-reviewed oncology journals and recognized non-profit trade associations such as the American Society of Clinical Oncology (ASCO) and the Association for Molecular Pathology (AMP).
Financial and corporate data are validated against standard databases including Bloomberg, Factiva, Hoovers, and PitchBook, ensuring consistency in company revenue baselines and M&A activity tracking.
We triangulate incidence and mortality datasets from the WHO International Agency for Research on Cancer (IARC) GLOBOCAN program with national cancer registries to calibrate testing-volume demand per indication and region.
All secondary benchmarks are cross-checked against our proprietary primary interview findings; where divergence exceeds 10%, the primary-derived estimate is retained and documented.
Demand Modeling & Market Estimation
We apply top-down and bottom-up methodologies simultaneously, validated via multi-level data triangulation. The top-down approach anchors on global oncology diagnostic expenditure and allocates to solid tumor testing by indication mix and sample modality.
The bottom-up build aggregates quantitative metrics including annual test volume per cancer indication, average revenue per test (ARPT) by technology tier (NGS, PCR, IHC, FISH), laboratory capacity utilization rates, and reimbursement coverage ratios by payer type.
Segment-level estimates are cross-validated across three independent data streams — manufacturer revenue disclosures, laboratory procedural volume surveys, and clinician-reported ordering behavior — with variances reconciled to a guaranteed estimated data accuracy level of 85–90%.
Regional forecasts incorporate country-specific regulatory timelines, including IVDR certification pathways in Europe and reimbursement code updates in the U.S. and Japan.
Data Accuracy & Quality Check
Every report undergoes a structured multi-level data triangulation process, comparing primary interview outputs against secondary institutional benchmarks and financial database records before finalization.
We maintain a guaranteed 85–90% estimated data accuracy level, with explicit confidence intervals disclosed for all forward-looking CAGR and market-size projections.
Every report is updated to the date of purchase, incorporating the latest regulatory approvals, product launches, reimbursement decisions, and corporate developments affecting the solid tumor testing landscape.
Our 6-step validation process includes expert panel review, outlier reconciliation, segment-sum consistency checks, and regional share arithmetic verification to ensure internal coherence across all published figures.
11.1.9.2. Products
11.1.9.3. Company Financials
11.1.9.4. SWOT Analysis
11.1.10. Illumina Inc.
11.1.10.1. Company Overview
11.1.10.2. Products
11.1.10.3. Company Financials
11.1.10.4. SWOT Analysis
11.1.11. MedGenome
11.1.11.1. Company Overview
11.1.11.2. Products
11.1.11.3. Company Financials
11.1.11.4. SWOT Analysis
11.1.12. Myriad Genetics Inc.
11.1.12.1. Company Overview
11.1.12.2. Products
11.1.12.3. Company Financials
11.1.12.4. SWOT Analysis
11.1.13. NeoGenomics Laboratories
11.1.13.1. Company Overview
11.1.13.2. Products
11.1.13.3. Company Financials
11.1.13.4. SWOT Analysis
11.1.14. QIAGEN N.V.
11.1.14.1. Company Overview
11.1.14.2. Products
11.1.14.3. Company Financials
11.1.14.4. SWOT Analysis
11.1.15. Quest Diagnostics Incorporated
11.1.15.1. Company Overview
11.1.15.2. Products
11.1.15.3. Company Financials
11.1.15.4. SWOT Analysis
11.1.16. SOPHiA GENETICS
11.1.16.1. Company Overview
11.1.16.2. Products
11.1.16.3. Company Financials
11.1.16.4. SWOT Analysis
11.1.17. Thermo Fisher Scientific Inc.
11.1.17.1. Company Overview
11.1.17.2. Products
11.1.17.3. Company Financials
11.1.17.4. SWOT Analysis
11.1.18. BGI Genomics
11.1.18.1. Company Overview
11.1.18.2. Products
11.1.18.3. Company Financials
11.1.18.4. SWOT Analysis
11.2. Market Entropy
11.2.1. Company's Key Areas Served
11.2.2. Recent Developments
11.3. Company Market Share Analysis, 2026
11.3.1. Top 5 Companies Market Share Analysis
11.3.2. Top 3 Companies Market Share Analysis
11.4. List of Potential Customers
Figure 17: Europe Solid Tumor Testing Market Revenue Share (%), by Application 2026 & 2034
Figure 18: Europe Solid Tumor Testing Market Revenue (Billion), by End User 2026 & 2034
Figure 19: Europe Solid Tumor Testing Market Revenue Share (%), by End User 2026 & 2034
Figure 20: Europe Solid Tumor Testing Market Revenue (Billion), by Sample Type 2026 & 2034
Figure 21: Europe Solid Tumor Testing Market Revenue Share (%), by Sample Type 2026 & 2034
Figure 22: Europe Solid Tumor Testing Market Revenue (Billion), by Technology 2026 & 2034
Figure 23: Europe Solid Tumor Testing Market Revenue Share (%), by Technology 2026 & 2034
Figure 24: Europe Solid Tumor Testing Market Revenue (Billion), by Country 2026 & 2034
Figure 25: Europe Solid Tumor Testing Market Revenue Share (%), by Country 2026 & 2034
Figure 26: Asia Pacific Solid Tumor Testing Market Revenue (Billion), by Type 2026 & 2034
Figure 27: Asia Pacific Solid Tumor Testing Market Revenue Share (%), by Type 2026 & 2034
Figure 28: Asia Pacific Solid Tumor Testing Market Revenue (Billion), by Application 2026 & 2034
Figure 29: Asia Pacific Solid Tumor Testing Market Revenue Share (%), by Application 2026 & 2034
Figure 30: Asia Pacific Solid Tumor Testing Market Revenue (Billion), by End User 2026 & 2034
Figure 31: Asia Pacific Solid Tumor Testing Market Revenue Share (%), by End User 2026 & 2034
Figure 32: Asia Pacific Solid Tumor Testing Market Revenue (Billion), by Sample Type 2026 & 2034
Figure 33: Asia Pacific Solid Tumor Testing Market Revenue Share (%), by Sample Type 2026 & 2034
Figure 34: Asia Pacific Solid Tumor Testing Market Revenue (Billion), by Technology 2026 & 2034
Figure 35: Asia Pacific Solid Tumor Testing Market Revenue Share (%), by Technology 2026 & 2034
Figure 36: Asia Pacific Solid Tumor Testing Market Revenue (Billion), by Country 2026 & 2034
Figure 37: Asia Pacific Solid Tumor Testing Market Revenue Share (%), by Country 2026 & 2034
Figure 38: South America Solid Tumor Testing Market Revenue (Billion), by Type 2026 & 2034
Figure 39: South America Solid Tumor Testing Market Revenue Share (%), by Type 2026 & 2034
Figure 40: South America Solid Tumor Testing Market Revenue (Billion), by Application 2026 & 2034
Figure 41: South America Solid Tumor Testing Market Revenue Share (%), by Application 2026 & 2034
Figure 42: South America Solid Tumor Testing Market Revenue (Billion), by End User 2026 & 2034
Figure 43: South America Solid Tumor Testing Market Revenue Share (%), by End User 2026 & 2034
Figure 44: South America Solid Tumor Testing Market Revenue (Billion), by Sample Type 2026 & 2034
Figure 45: South America Solid Tumor Testing Market Revenue Share (%), by Sample Type 2026 & 2034
Figure 46: South America Solid Tumor Testing Market Revenue (Billion), by Technology 2026 & 2034
Figure 47: South America Solid Tumor Testing Market Revenue Share (%), by Technology 2026 & 2034
Figure 48: South America Solid Tumor Testing Market Revenue (Billion), by Country 2026 & 2034
Figure 49: South America Solid Tumor Testing Market Revenue Share (%), by Country 2026 & 2034
Figure 50: Middle East & Africa Solid Tumor Testing Market Revenue (Billion), by Type 2026 & 2034
Figure 51: Middle East & Africa Solid Tumor Testing Market Revenue Share (%), by Type 2026 & 2034
Figure 52: Middle East & Africa Solid Tumor Testing Market Revenue (Billion), by Application 2026 & 2034
Figure 53: Middle East & Africa Solid Tumor Testing Market Revenue Share (%), by Application 2026 & 2034
Figure 54: Middle East & Africa Solid Tumor Testing Market Revenue (Billion), by End User 2026 & 2034
Figure 55: Middle East & Africa Solid Tumor Testing Market Revenue Share (%), by End User 2026 & 2034
Figure 56: Middle East & Africa Solid Tumor Testing Market Revenue (Billion), by Sample Type 2026 & 2034
Figure 57: Middle East & Africa Solid Tumor Testing Market Revenue Share (%), by Sample Type 2026 & 2034
Figure 58: Middle East & Africa Solid Tumor Testing Market Revenue (Billion), by Technology 2026 & 2034
Figure 59: Middle East & Africa Solid Tumor Testing Market Revenue Share (%), by Technology 2026 & 2034
Figure 60: Middle East & Africa Solid Tumor Testing Market Revenue (Billion), by Country 2026 & 2034
Figure 61: Middle East & Africa Solid Tumor Testing Market Revenue Share (%), by Country 2026 & 2034
Table 17: Europe Solid Tumor Testing Market Revenue Billion Forecast, by Application 2020 & 2034
Table 18: Europe Solid Tumor Testing Market Revenue Billion Forecast, by End User 2020 & 2034
Table 19: Europe Solid Tumor Testing Market Revenue Billion Forecast, by Sample Type 2020 & 2034
Table 20: Europe Solid Tumor Testing Market Revenue Billion Forecast, by Technology 2020 & 2034
Table 21: Europe Solid Tumor Testing Market Revenue Billion Forecast, by Country 2020 & 2034
Solid Tumor Testing Market.jpg){kind=small}
